Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.
- Androgen receptor
- Androgen receptor–directed therapies
- Castration-resistant prostate cancer
- Plasma DNA
ASJC Scopus subject areas